27,784 Shares of Artivion, Inc. $AORT Purchased by Inspire Investing LLC

Inspire Investing LLC bought a new position in Artivion, Inc. (NYSE:AORT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 27,784 shares of the company’s stock, valued at approximately $634,000. Inspire Investing LLC owned about 0.06% of Artivion as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the company. Rockefeller Capital Management L.P. increased its position in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares during the last quarter. Amundi boosted its holdings in shares of Artivion by 7.5% in the first quarter. Amundi now owns 7,186 shares of the company’s stock worth $263,000 after buying an additional 501 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Artivion by 38.0% in the third quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock worth $48,000 after buying an additional 584 shares during the last quarter. Arizona State Retirement System grew its position in Artivion by 6.2% during the second quarter. Arizona State Retirement System now owns 11,709 shares of the company’s stock valued at $263,000 after buying an additional 684 shares during the period. Finally, Cetera Investment Advisers grew its position in Artivion by 10.8% during the first quarter. Cetera Investment Advisers now owns 9,817 shares of the company’s stock valued at $359,000 after buying an additional 958 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Artivion Stock Performance

Shares of NYSE AORT opened at $23.37 on Friday. The firm has a fifty day moving average price of $23.98 and a 200-day moving average price of $29.56. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The stock has a market cap of $1.14 billion, a PE ratio of 42.44 and a beta of 1.23. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Equities analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Artivion news, SVP Andrew Green sold 11,480 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the sale, the senior vice president directly owned 40,160 shares of the company’s stock, valued at $1,002,795.20. This trade represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James Mackin sold 70,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 90,460 shares of company stock worth $2,557,366. Corporate insiders own 6.30% of the company’s stock.

Analysts Set New Price Targets

AORT has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Jefferies Financial Group started coverage on Artivion in a research note on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price objective for the company. Finally, Canaccord Genuity Group raised their target price on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.86.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.